A multi-stakeholder consensus roadmap was published in the British Journal of Cancer to guide clinical trial design for rare childhood central nervous system tumors. The effort targets structural barriers that can slow development in small populations, including making trials more practical and more inclusive. The roadmap frames trial execution as a systems problem—how stakeholders coordinate endpoints, enrollment pathways, and trial infrastructure when conditions are heterogeneous and patient numbers are limited. For sponsors and investigators, the document is positioned as actionable guidance rather than only descriptive analysis. As the oncology pipeline expands in pediatric neuro-oncology, the consensus may help reduce friction between scientific pacing and the clinical-trial systems available for rare diseases.